Soligenix Inc
NASDAQ:SNGX
Relative Value
The Relative Value of one SNGX stock under the Base Case scenario is 1.477 USD. Compared to the current market price of 0.4118 USD, Soligenix Inc is Undervalued by 72%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
SNGX Competitors Multiples
Soligenix Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Soligenix Inc
NASDAQ:SNGX
|
4.3m USD | 5.1 | -0.7 | 0.4 | 0.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
160.6B USD | 5.4 | 42.7 | 18.2 | 29.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.6B USD | 8.1 | 27.4 | 22.1 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | ||
AU |
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.7 | 21.6 | 26.8 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.8B USD | 9.1 | -7.8 | -8.5 | -7.6 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | ||
KR |
Celltrion Inc
KRX:068270
|
40.2T KRW | 18.5 | 75.1 | 45.9 | 63.2 |